Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression

NCT03251690 is registered in ClinicalTrials.gov with Mahidol University as lead sponsor.

NCT NCT03251690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03251690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression
Lead sponsor
Mahidol University
Phase
Not applicable
Overall status
Completed
Start date
October 27, 2016
Completion date
April 30, 2018
Enrollment
246 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anti-retroviral agents, dyslipidemias, efavirenz, hiv-1-infection, rilpivirine, sustained virologic response